Patents by Inventor William E. Neway, III

William E. Neway, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Edg receptor agonists
    Patent number: 7479504
    Abstract: The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: January 20, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Robert L. Bugianesi, George A. Doherty, Amy Gentry, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
  • Aminoalkylphosphonates and related compounds as Edg receptor agonists
    Patent number: 7309721
    Abstract: The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: December 18, 2007
    Assignee: Merck + Co., Inc.
    Inventors: Richard J. Budhu, George A. Doherty, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
  • 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
    Patent number: 7199142
    Abstract: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: April 3, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Weirong Chen, Jeffrey J. Hale, Zhen Li, Christopher L. Lynch, Sander G. Mills, William E. Neway, III